Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31503658 | 0.91 | USP2 (0.36) | GRIN2BGRIN2CCTSKUSP2SMN1; SMN2 | |
| SCHEMBL27092776 | 0.87 | GRIN2B (0.39) | GRIN2BGRIN2CCTSKUSP2SMN1; SMN2 | |
| SCHEMBL442695 | 0.85 | GRIN2B (0.41) | GRIN2BGRIN2CCTSKUSP2SMN1; SMN2 | |
| SCHEMBL444540 | 0.84 | GRIN2B (0.38) | GRIN2BGRIN2CCTSKUSP2SMN1; SMN2 | |
| SCHEMBL444153 | 0.83 | GRIN2B (0.45) | GRIN2BGRIN2CCTSKUSP2SMN1; SMN2 | |
| SCHEMBL24999579 | 0.82 | CTSK (0.37) | GRIN2BGRIN2CCTSKUSP2SMN1; SMN2 | |
| SCHEMBL20330502 | 0.82 | GRIN2B (0.37) | GRIN2BGRIN2CCTSKUSP2SMN1; SMN2 | |
| SCHEMBL444285 | 0.82 | NR1H2 (0.40) | GRIN2BGRIN2CCTSKSMN1; SMN2JAK3 | |
| SCHEMBL441772 | 0.82 | GRIN2B (0.37) | GRIN2BGRIN2CCTSKUSP2SMN1; SMN2 | |
| SCHEMBL27219247 | 0.82 | GRIN2B (0.37) | GRIN2BGRIN2CCTSKUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | GRIN2B 699/4885GRIN2C 2536/4885CTSK 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.